Advertisement
Home »

Neoadjuvant Nivolumab/Ipilimumab Outperforms Adjuvant Anti-PD-1 Therapy in Stage III Resectable Melanoma

Sep 30, 2024

REFERENCES & ADDITIONAL READING

  1. Blank CU, et al. N Engl J Med. 2024;Jun 2.Online ahead of print.
  2. Lucas M, et al. Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: the NADINA trial. Abstract LBA42. ESMO Congress 2024, 13–17 September, Barcelona, Spain.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement